



Eurofins Biopharma Products Testing Denmark A/S

Smedeskovej 38
8464 Galten
CVR No. 29428689

Annual report 2024

The Annual General Meeting adopted the
annual report on 23.05.2025

Svend Aage Linde
Chairman

Contents

Entity details	2
Statement by Management	3
Independent auditor's report	4
Management commentary	7
Income statement for 2024	9
Balance sheet at 31.12.2024	10
Statement of changes in equity for 2024	12
Notes	13
Accounting policies	17

Entity details

Entity

Eurofins Biopharma Products Testing Denmark A/S
Smedeskovvej 38
8464 Galten

Business Registration No.: 29428689
Registered office: Skanderborg
Financial year: 01.01.2024 - 31.12.2024

Board of Directors

Svend Aage Linde
Jan Rando
Stina Hansen
Jeppe Andersen Jacomo
Jacob Sickmann Ransborg

Executive Board

Jan Rando

Auditors

Deloitte Statsautoriseret Revisionspartnerselskab
City Tower, Værkmestergade 2
8000 Aarhus C

Statement by Management

The Board of Directors and the Executive Board have today considered and approved the annual report of Eurofins Biopharma Products Testing Denmark A/S for the financial year 01.01.2024 - 31.12.2024.

The annual report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2024 and of the results of its operations for the financial year 01.01.2024 - 31.12.2024.

We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

We recommend the annual report for adoption at the Annual General Meeting.

Galten, 23.05.2025

Executive Board

Jan Rando

Board of Directors

Svend Aage Linde

Jan Rando

Stina Hansen

Jeppe Andersen Jacomo

Jacob Sickmann Ransborg

Independent auditor's report

To the shareholders of Eurofins Biopharma Products Testing Denmark A/S

Opinion

We have audited the financial statements of Eurofins Biopharma Products Testing Denmark A/S for the financial year 01.01.2024 - 31.12.2024, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2024 and of the results of its operations for the financial year 01.01.2024 - 31.12.2024 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of this auditor's report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required by relevant law and regulations.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements in the relevant law and regulations. We did not identify any material misstatement of the management commentary.

Aarhus, 23.05.2025

Deloitte

Statsautoriseret Revisionspartnerselskab

CVR No. 33963556

Henrik Vedel

State Authorised Public Accountant

Identification No (MNE) mne10052

Lars Dam Østergaard

State Authorised Public Accountant

Identification No (MNE) mne34501

Management commentary

Financial highlights

	2024	2023	2022	2021	2020
	DKK'000	DKK'000	DKK'000	DKK'000	DKK'000
Key figures					
Gross profit/loss	64,991	54,477	65,199	56,378	51,639
Operating profit/loss	14,686	2,995	12,641	14,886	13,184
Net financials	(903)	(1,390)	(441)	(55)	(676)
Profit/loss for the year	10,743	1,247	9,512	11,555	9,757
Total assets	86,649	64,488	60,863	49,312	44,879
Investments in property, plant and equipment	3,718	8,681	17,334	3,389	2,519
Equity	22,550	12,807	18,061	18,549	12,994
Average number of employees	75	90	95	77	71
Ratios					
Return on assets (%)	16.96	4.60	20.80	30.20	29.40
Return on equity (%)	60.77	8.08	51.96	73.27	84.00
Equity ratio (%)	26.02	19.86	29.67	37.62	28.95

Financial highlights are defined and calculated in accordance with the current version of "Recommendations & Ratios" issued by the CFA Society Denmark.

Return on assets (%):

$\frac{\text{Profit before financials} * 100}{\text{Total assets}}$

Return on equity (%):

$\frac{\text{Profit/loss for the year} * 100}{\text{Average equity}}$

Equity ratio (%):

$\frac{\text{Equity} * 100}{\text{Total assets}}$

Primary activities

Eurofins Biopharma Product Testing Denmark A/S main activities include investigations, laboratory testing and consultancy within the pharmaceutical area and mainly according to the GMP.

Development in activities and finances

The Company has in 2024 had sufficient staff resources to safeguard stable and qualified services to our customers. However, the Company has in 2024 noticed an increasing pressure on the labor market and has focused on training and personal development to sustain a strong team of specialists and key employees.

Furthermore, the Company has - together with other companies in the Eurofins Group - invested heavily in development of leader talents. These initiatives together with continued focusing on improvement of products and processes and ensuring high quality service to our customers, mean that Eurofins Biopharma Product Testing Denmark is well positioned for the future on knowledge, capacity and resources.

Profit/loss for the year in relation to expected developments

The Annual Report 2024 shows a profit of DKK 10.742.824, which is considered satisfactory. The increase in profit is in line with the expectations set out in the annual report 2023.

Outlook

The Company will in 2025 focus on increasing sales to Danish and international customers and continue building even stronger relationship with our customers by delivering high quality services meeting our customers present and future needs.

In parallel, focus will continue being on improving efficiency in processes and production and reducing our climate impact by reducing energy consumption and by local production of green energy production.

The broad portfolio of services, tests and methods will be sustained and enlarged as required to meet our customers' demands.

The Company expects sales to grow by 10-15% in 2025 and net profit to reach a level of 12-15 mDKK.

Events after the balance sheet date

No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.

Income statement for 2024

	Notes	2024 DKK	2023 DKK
Gross profit/loss		64,991,261	54,476,694
Staff costs	2	(45,234,387)	(47,588,643)
Depreciation, amortisation and impairment losses		(5,070,397)	(3,892,851)
Operating profit/loss		14,686,477	2,995,200
Other financial income	3	942,049	815,899
Other financial expenses	4	(1,844,889)	(2,206,135)
Profit/loss before tax		13,783,637	1,604,964
Tax on profit/loss for the year	5	(3,040,813)	(358,356)
Profit/loss for the year	6	10,742,824	1,246,608

Balance sheet at 31.12.2024

Assets

	Notes	2024 DKK	2023 DKK
Acquired intangible assets		255,013	661,867
Intangible assets	7	255,013	661,867
Other fixtures and fittings, tools and equipment		7,429,605	7,095,686
Leasehold improvements		17,149,931	19,140,106
Property, plant and equipment in progress		710,222	900,166
Property, plant and equipment	8	25,289,758	27,135,958
Deposits		1,376,800	1,376,800
Financial assets	9	1,376,800	1,376,800
Fixed assets		26,921,571	29,174,625
Raw materials and consumables		879,105	622,088
Inventories		879,105	622,088
Trade receivables		30,516,168	17,127,791
Contract work in progress		2,343,087	3,087,614
Receivables from group enterprises	10	25,013,442	13,164,511
Deferred tax	11	548,922	54,734
Other receivables		355,336	263,961
Joint taxation contribution receivable		0	889,646
Prepayments	12	71,765	102,690
Receivables		58,848,720	34,690,947
Current assets		59,727,825	35,313,035
Assets		86,649,396	64,487,660

Equity and liabilities

	Notes	2024 DKK	2023 DKK
Contributed capital		700,000	700,000
Retained earnings		11,150,268	11,107,444
Proposed dividend		10,700,000	1,000,000
Equity		22,550,268	12,807,444
Payables to group enterprises		0	26,955,188
Other payables		3,497,553	3,491,291
Non-current liabilities other than provisions	13	3,497,553	30,446,479
Bank loans		2,575	74,033
Prepayments received from customers		2,748,182	211,641
Trade payables		5,459,222	6,181,938
Payables to group enterprises	14	34,342,881	5,387,870
Joint taxation contribution payable		3,532,655	0
Other payables		14,516,060	9,378,255
Current liabilities other than provisions		60,601,575	21,233,737
Liabilities other than provisions		64,099,128	51,680,216
Equity and liabilities		86,649,396	64,487,660
Events after the balance sheet date	1		
Unrecognised rental and lease commitments	15		
Contingent liabilities	16		
Non-arm's length related party transactions	17		
Group relations	18		

Statement of changes in equity for 2024

	Contributed capital DKK	Retained earnings DKK	Proposed dividend DKK	Total DKK
Equity beginning of year	700,000	11,107,444	1,000,000	12,807,444
Ordinary dividend paid	0	0	(1,000,000)	(1,000,000)
Profit/loss for the year	0	42,824	10,700,000	10,742,824
Equity end of year	700,000	11,150,268	10,700,000	22,550,268

Notes

1 Events after the balance sheet date

No events materially affecting the assessment of the Annual Report have occurred after the Balance sheet date.

2 Staff costs

	2024 DKK	2023 DKK
Wages and salaries	41,204,757	43,329,719
Pension costs	3,144,838	3,281,062
Other social security costs	884,792	977,862
	45,234,387	47,588,643
Average number of full-time employees	75	90

Remuneration to the Executive board has not been disclosed in accordance with section 98 8(3) of the Danish Financial Statements Act.

3 Other financial income

	2024 DKK	2023 DKK
Financial income from group enterprises	576,981	431,692
Exchange rate adjustments	365,068	384,207
	942,049	815,899

4 Other financial expenses

	2024 DKK	2023 DKK
Financial expenses from group enterprises	1,613,558	1,384,239
Exchange rate adjustments	219,169	577,188
Other financial expenses	12,162	244,708
	1,844,889	2,206,135

5 Tax on profit/loss for the year

	2024 DKK	2023 DKK
Current tax	3,532,655	110,354
Change in deferred tax	(491,842)	248,002
	3,040,813	358,356

6 Proposed distribution of profit and loss

	2024	2023
	DKK	DKK
Ordinary dividend for the financial year	10,700,000	1,000,000
Retained earnings	42,824	246,608
	10,742,824	1,246,608

7 Intangible assets

	Acquired intangible assets DKK
Cost beginning of year	1,977,489
Cost end of year	1,977,489
Amortisation and impairment losses beginning of year	(1,315,622)
Amortisation for the year	(406,854)
Amortisation and impairment losses end of year	(1,722,476)
Carrying amount end of year	255,013

8 Property, plant and equipment

	Other fixtures and fittings, tools and equipment DKK	Leasehold improvements DKK	Property, plant and equipment in progress DKK
Cost beginning of year	32,101,994	28,942,699	900,166
Transfers	0	0	(900,166)
Additions	2,650,275	357,012	710,222
Cost end of year	34,752,269	29,299,711	710,222
Depreciation and impairment losses beginning of year	(25,006,308)	(9,802,593)	0
Depreciation for the year	(2,316,356)	(2,347,187)	0
Depreciation and impairment losses end of year	(27,322,664)	(12,149,780)	0
Carrying amount end of year	7,429,605	17,149,931	710,222

9 Financial assets

	Deposits DKK
Cost beginning of year	1,376,800
Cost end of year	1,376,800
Carrying amount end of year	1,376,800

10 Receivables from group enterprises

The Company is a part of cash pool with Eurofins NSC Denmark A/S. Receivable from this cash pool is included in receivables from group enterprises and amounts to 24,1 MDKK (2023: 9,8 MDKK).

11 Deferred tax

	2024	2023
	DKK	DKK
Changes during the year		
Beginning of year	54,734	302,736
Recognised in the income statement	494,188	(248,002)
End of year	548,922	54,734

Deferred tax assets

Any changes in deferred tax due to changes to tax rates are recognised in the income statement.

12 Prepayments

Prepayments comprise prepaid expenses concerning rent, insurance premiums, subscriptions and interest etc.

13 Non-current liabilities other than provisions

	Due after more than 12 months	Outstanding after 5 years
	2024	2024
	DKK	DKK
Other payables	3,497,553	3,497,553
	3,497,553	3,497,553

14 Payables to group enterprises

The classification as a short-term liability can be attributed to the fact that management has not obtained a written confirmation by the balance sheet date that the company has an unconditional right to defer the payment of the intra-group debt for more than 12 months from the balance sheet date. However, similar to previous years, it is management's expectation that the company's intra-group debt will not be settled during the upcoming financial year.

15 Unrecognised rental and lease commitments

	2024	2023
	DKK	DKK
Liabilities under rental or lease agreements until maturity in total	26,383,756	29,296,441

Total future operating leases payments: 593,978 DKK

Total future rental obligations: 25,789,778 DKK

16 Contingent liabilities

The Entity participates in a Danish joint taxation arrangement where Eurofins NSC Denmark A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore liable for income taxes etc for the jointly taxed entities, and for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed entities. The jointly taxed entities' total

known net liability under the joint taxation arrangement is disclosed in the administration company's financial statements.

17 Non-arm's length related party transactions

Only related party transactions not conducted on an arm's length basis are disclosed in the annual report. No such transactions have been conducted in the financial year.

18 Group relations

Copies of the consolidated financial statements of Eurofins scientific S.E. may be ordered at the following address: 23, Val Fleuri, L-1526, Luxembourg

Accounting policies

Reporting class

This annual report has been prepared in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium).

The accounting policies applied to these financial statements are consistent with those applied last year.

Recognition and measurement

Assets are recognised in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Entity, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year.

Danish kroner is used as the measurement currency. All other currencies are regarded as foreign currencies.

Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the balance sheet date, are recognised in the income statement as financial income or financial expenses.

Income statement

Gross profit or loss

Gross profit or loss comprises revenue, changes in inventories of finished goods and work in progress, own work capitalised, other operating income, cost of raw materials and consumables and external expenses.

Revenue

With reference to section 32 of the Danish Financial Statements Act, revenue has not been disclosed in the Annual Report

Revenue from the sale of services is recognised in the income statement when delivery is made to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration

fixed.

Contract work in progress is included in revenue based on the stage of completion so that revenue corresponds to the selling price of the work performed in the financial year (the percentage-of-completion method).

Other operating income

Other operating income comprises income of a secondary nature as viewed in relation to the Entity's primary activities.

Cost of sales

Cost of sales comprises goods consumed in the financial year measured at cost, adjusted for normal inventory writedowns.

Other external expenses

Other external expenses include expenses relating to the Entity's normal activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.

Staff costs

Staff costs comprise salaries and wages, and social security contributions, pension contributions, etc for entity staff.

Depreciation, amortisation and impairment losses

Depreciation, amortisation and impairment losses relating to property, plant and equipment and intangible assets comprise depreciation, amortisation and impairment losses for the financial year.

Other financial income

Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital or exchange gains on payables and transactions in foreign currencies, amortisation of financial assets, and tax relief under the Danish Tax Prepayment Scheme etc.

Other financial expenses

Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital or exchange losses on payables and transactions in foreign currencies, amortisation of financial liabilities, and tax surcharge under the Danish Tax Prepayment Scheme etc.

Tax on profit/loss for the year

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.

The Entity is jointly taxed with all Danish group enterprises. The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses).

Balance sheet

Intellectual property rights etc

Intellectual property rights etc comprise development projects completed and in progress with related intellectual property rights.

Intellectual property rights acquired are measured at cost less accumulated amortisation. Patents are amortised on a straight-line basis over their remaining duration, and licences are amortised over the term of the agreement.

Intellectual property rights etc are written down to the lower of recoverable amount and carrying amount.

Property, plant and equipment

Land and buildings, plant and machinery, and other fixtures and fittings, tools and equipment are measured at cost less accumulated depreciation and impairment losses. Land is not depreciated.

Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be put into operation.

The basis of depreciation is cost less estimated residual value after the end of useful life. Straight-line depreciation is made on the basis of the following estimated useful lives of the assets:

	Useful life
Other fixtures and fittings, tools and equipment	3-10 years
Leasehold improvements	5-15 years

For leasehold improvements and assets subject to finance leases, the depreciation period cannot exceed the contract period.

Estimated useful lives and residual values are reassessed annually.

Items of property, plant and equipment are written down to the lower of recoverable amount and carrying amount.

Inventories

Inventories are measured at the lower of cost using the FIFO method and net realisable value.

Cost consists of purchase price plus delivery costs.

The net realisable value of inventories is calculated as the estimated selling price less completion costs and costs incurred to execute sale.

Receivables

Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.

Contract work in progress

Contract work in progress is measured at the selling price of the work carried out at the balance sheet date.

The selling price is measured based on the stage of completion and the total estimated income from the individual contracts in progress. Usually, the stage of completion is determined as the ratio of actual to total budgeted consumption of resources.

If the selling price of a project in progress cannot be made up reliably, it is measured at the lower of costs incurred and net realisable value.

Each contract in progress is recognised in the balance sheet in receivables or liabilities other than provisions, depending on whether the net value, calculated as the selling price less prepayments received, is positive or negative.

Costs of sales work and of securing contracts, and finance costs are recognised in the income statement as incurred.

Deferred tax

Deferred tax is recognised on all temporary differences between the carrying amount and the tax-based value of assets and liabilities, for which the tax-based value is calculated based on the planned use of each asset.

Deferred tax assets, including the tax base of tax loss carryforwards, are recognised in the balance sheet at their estimated realisable value, either as a set-off against deferred tax liabilities or as net tax assets.

Joint taxation contributions receivable or payable

Current joint taxation contributions payable or joint taxation contributions receivable are recognised in the balance sheet, calculated as tax computed on the taxable income for the year, which has been adjusted for prepaid tax. For tax losses, joint taxation contributions receivable are only recognised if such losses are expected to be used under the joint taxation arrangement.

Prepayments

Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.

Dividend

Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity.

Operating leases

Lease payments on operating leases are recognised on a straight-line basis in the income statement over the term of the lease.

Other financial liabilities

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.

Prepayments received from customers

Prepayments received from customers comprise amounts received from customers prior to delivery of the goods agreed or completion of the service agreed.

Cash flow statement

Referring to section 86(4) of the Danish Financial Statements Act, the Entity has prepared no cash flow statement as such statement is included in the consolidated cash flow statement of Eurofins Scientific S.E., 23, Val Fleuri, L-1526, Luxembourg,